EVH projects 2027 revenue growth exceeding 25% and adjusted EBITDA midpoint at or above $150 million.
Evolent Health outlined a 2027 financial outlook targeting over 25% revenue growth and an adjusted EBITDA midpoint of at least $150 million. The company reported Q2 2026 total revenue of $653 million and adjusted EBITDA of $28 million, reflecting strong execution on prior commitments.
In the second quarter, Evolent’s results aligned with management’s expectations, demonstrating progress toward long-term goals. The 2027 projections signal confidence in sustained growth amid ongoing operational improvements.
No immediate market reaction was detailed in the earnings call summary.